CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 51 enrolled
Drug / intervention
Esomeprazole +3 moredrug
Likely dose
Esomeprazole 0.4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05861687
NCT05861687Phase 3Completed
CompareCT.gov

Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials

Finni Kollins·interventional·Posted May 17, 2023·Updated May 17, 2023

In Brief

A Phase 3 clinical trial evaluating Esomeprazole, Lansoprazole, and 2 other interventions for Helicobacter Pylori Infection. Completed, enrolled 51 participants across 2 sites.

Detailed Summary

This study aims to compare the recurrence rates of Esomeprazole and Lansoprazole in triple combination therapy to eradicate H.pylori infection in children. The participants were divided into two groups, those who received Esomeprazole and those who received Lansoprazole

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHelicobacter Pylori Infection
CountriesIndonesia
Collaborators--

Timeline

Phase 3CompletedFinished
20222023202420252026
First PostedMay 17, 2023
Enrollment StartAug 1, 2021
Primary CompletionDec 7, 2021
Study CompletionMay 20, 2022
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.1 years ago

Interventions

Esomeprazoledrug

Administered once a day per-oral (PO) with the dose of 0.4 mg/kg

Lansoprazoledrug

Administered once a day per-oral (PO) with the dose of 15 mg if individual's body mass was \<30 kg, and 30 mg if it was \>30 kg

Amoxicillindrug

Administered thrice a day per-oral (PO) with the dose of 25 mg/kg

Clarithromycindrug

Administered twice a day per-oral with the dose of 7.5 mg/kg